2023-07-19 19:05:00
Title: New Alzheimer’s Drug Shows Promise in Slowing Disease Progression
Date: 07/19/2023
By: Nadja Austel
Frankfurt – According to recent studies, a new Alzheimer’s drug developed by US pharmaceutical company Eli Lilly has shown significant potential in slowing down the progression of the disease. Early diagnosis is considered crucial for successful treatment.
The pharmaceutical company conducted a study in collaboration with several universities, involving over 1700 participants. The results revealed that individuals who received the drug donanemab experienced approximately 35 percent less cognitive impairment compared to those who received a placebo. The treatment involved a monthly infusion of donanemab for a total of 18 months.
One significant finding from the study indicated that the drug reduced beta-amyloid deposits in the brain, a characteristic feature of Alzheimer’s, by an average of 84 percent after 18 months, while the placebo group only experienced a 1 percent decrease.
Experts emphasize the importance of early Alzheimer’s diagnosis, as the earlier the disease is detected, the better the treatment outcomes. Current research suggests that initial signs of Alzheimer’s can appear up to nine years before an official diagnosis.
The potential slowing down of cognitive decline by 35 percent could enable individuals with Alzheimer’s to continue performing everyday tasks such as managing finances, household chores, and shopping independently. This breakthrough could significantly improve the quality of life for millions of people worldwide.
The World Health Organization estimates that at least 30 million people globally suffer from Alzheimer’s. In Germany alone, Alzheimer’s affects around two-thirds of the approximately 1.8 million people with dementia.
The British research institute Alzheimer’s Research also conducted a study on the new drug donanemab, yielding positive results. The institute expressed optimism about entering a new era in which Alzheimer’s could become a treatable disease. The Alzheimer’s Society charity shares a similar view, stating that drugs like donanemab could mark the beginning of the end for Alzheimer’s disease, comparing it to long-term conditions such as asthma or diabetes.
While the study results are promising, the pharmaceutical company identified a small number of individuals who experienced serious side effects, including brain swelling. Additionally, three deaths in the donanemab group and one death in the placebo group were classified as “treatment-related.” Further research is necessary to minimize treatment risks associated with the Alzheimer’s drug.
Despite these setbacks, the results represent a significant breakthrough in Alzheimer’s research. Dr. Richard Oakley, Associate Research Director of the Alzheimer’s Society, hailed this development as a game-changer in the fight against Alzheimer’s, demonstrating that it is possible to slow down the disease’s progression. Drugs like donanemab could lead to a future where Alzheimer’s is considered a long-term condition, allowing affected individuals to live full lives.
Disclaimer: This article provides general information about Alzheimer’s research and is not intended for self-diagnosis, treatment, or medication. Consultation with a healthcare professional is necessary for specific clinical inquiries.]
#drug #slows #disease